ATE462697T1 - Bisaryl-sulfonamide - Google Patents
Bisaryl-sulfonamideInfo
- Publication number
- ATE462697T1 ATE462697T1 AT05790029T AT05790029T ATE462697T1 AT E462697 T1 ATE462697 T1 AT E462697T1 AT 05790029 T AT05790029 T AT 05790029T AT 05790029 T AT05790029 T AT 05790029T AT E462697 T1 ATE462697 T1 AT E462697T1
- Authority
- AT
- Austria
- Prior art keywords
- pparδ
- pparγ
- prevention
- compounds
- treatment
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 108010015181 PPAR delta Proteins 0.000 abstract 2
- 108010016731 PPAR gamma Proteins 0.000 abstract 2
- 102000000536 PPAR gamma Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/58—Two sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60157804P | 2004-08-12 | 2004-08-12 | |
| PCT/US2005/028673 WO2006020830A2 (en) | 2004-08-12 | 2005-08-11 | Bisaryl-sulfonamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE462697T1 true ATE462697T1 (de) | 2010-04-15 |
Family
ID=35908167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05790029T ATE462697T1 (de) | 2004-08-12 | 2005-08-11 | Bisaryl-sulfonamide |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7544702B2 (de) |
| EP (1) | EP1786782B1 (de) |
| AT (1) | ATE462697T1 (de) |
| AU (1) | AU2005272786B2 (de) |
| CA (1) | CA2576993C (de) |
| DE (1) | DE602005020313D1 (de) |
| ES (1) | ES2343640T3 (de) |
| WO (1) | WO2006020830A2 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| CA2576993C (en) | 2004-08-12 | 2013-09-24 | Amgen Inc. | Bisaryl-sulfonamides |
| EP2079713B1 (de) * | 2006-10-04 | 2014-04-16 | F. Hoffmann-La Roche AG | Verfahren zur synthese von phenoxy-diaminopyrimidin-derivaten |
| CN101863830B (zh) * | 2010-06-22 | 2012-07-25 | 浙江科源化工有限公司 | 2-氨基-5-溴异烟酸的合成方法 |
| CN102321016B (zh) * | 2011-07-29 | 2013-04-10 | 山东轻工业学院 | 5-溴-2-羟基异烟酸甲酯的合成方法 |
| EP2773641B1 (de) * | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biarylethersulfonamide und ihre verwendung als arzneimittel |
| WO2013064983A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| SG11201408284VA (en) | 2012-05-22 | 2015-02-27 | Xenon Pharmaceuticals Inc | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| US9493429B2 (en) | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| AU2014356967A1 (en) | 2013-11-27 | 2016-07-07 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| BR112017024853A2 (pt) | 2015-05-22 | 2018-08-07 | Genentech Inc | composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| JP2018535234A (ja) | 2015-11-25 | 2018-11-29 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル遮断薬として有用な置換ベンズアミド |
| WO2017172802A1 (en) | 2016-03-30 | 2017-10-05 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| SG11201903348UA (en) | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| EP3759098A1 (de) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridinsulfonamidverbindungen und deren verwendung gegen schmerz und verwandte störungen |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| US12398097B2 (en) | 2019-07-29 | 2025-08-26 | Vanderbilt University | WDR5-MYC inhibitors |
| CN113773247A (zh) * | 2021-07-23 | 2021-12-10 | 无锡海伦生物科技有限公司 | 一种2-氨基-5-碘吡啶的制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB824598A (en) | 1957-02-14 | 1959-12-02 | Rhone Poulenc Sa | Improvements in or relating to new phenthiazine derivatives and processes for their preparation |
| BE577515A (fr) | 1959-04-09 | 1959-10-09 | Henri Morren | Dérives de pyridazine. |
| US4096264A (en) * | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
| EP0173361B1 (de) | 1984-08-11 | 1988-10-19 | Agfa-Gevaert N.V. | Organische Verbindungen zur Verwendung in einem Farbdiffusionsübertragungsverfahren und solche Verbindungen enthaltende photographische Elemente |
| CS254541B1 (cs) * | 1986-05-04 | 1988-01-15 | Alois Novacek | Sulfonamidy na bázi trimethoprimu |
| US5112971A (en) | 1988-08-10 | 1992-05-12 | Sumitomo Chemical Company, Limited | Anthraquinone dye compounds having fibers reactive group |
| FR2650275A1 (fr) * | 1989-07-28 | 1991-02-01 | Shimi Ibrahim | Nouveaux derives sulfamides, leur procede d'obtention et leur application comme medicament |
| US5403816A (en) * | 1990-10-25 | 1995-04-04 | Kumiai Chemical Industry Co., Ltd. | Picolinic acid derivative and herbicidal composition |
| US5902726A (en) * | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
| JPH10114744A (ja) * | 1996-08-22 | 1998-05-06 | Takeda Chem Ind Ltd | アミノグアニジンヒドラゾン誘導体、その製法及び剤 |
| US6646008B1 (en) * | 1996-12-31 | 2003-11-11 | The Salk Institute For Biological Studies | Treatment of disease states which result from neoplastic cell proliferation using PPAR-γ activators and compositions useful therefor |
| EP1053227B1 (de) * | 1998-01-29 | 2008-11-05 | Amgen Inc. | Ppar-gamma modulatoren |
| AU7583098A (en) | 1998-05-20 | 1999-12-06 | Eli Lilly And Company | Anti-viral compounds |
| US6248781B1 (en) * | 1998-10-21 | 2001-06-19 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
| WO2000046203A2 (en) * | 1999-02-04 | 2000-08-10 | Millennium Pharmaceuticals, Inc. | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
| CN1171872C (zh) | 1999-06-30 | 2004-10-20 | 图拉列克股份有限公司 | 调节PPARγ活性的化合物 |
| US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| ATE260912T1 (de) * | 1999-09-08 | 2004-03-15 | Glaxo Group Ltd | Oxazol ppar antagonisten |
| JP2001083656A (ja) | 1999-09-13 | 2001-03-30 | Konica Corp | プリントアウトを改良した熱現像感光材料 |
| JP2001089412A (ja) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| CA2383140C (en) * | 1999-09-24 | 2007-12-04 | Kyorin Pharmaceutical Co., Ltd. | Ppar.alpha. and ppar.gamma. inhibitors |
| EP1296967B1 (de) * | 2000-06-28 | 2006-05-31 | Amgen Inc. | Benzothiazolyl ppar-gamma modulatoren |
| GB0024361D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| US6756399B2 (en) * | 2001-06-29 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents |
| US6869967B2 (en) * | 2001-07-30 | 2005-03-22 | Novo Nordisk A/S | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives |
| US6869975B2 (en) * | 2001-09-14 | 2005-03-22 | Tularik Inc. | Linked biaryl compounds |
| TWI328007B (en) | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
| PA8594401A1 (es) * | 2003-02-21 | 2004-09-16 | Pfizer | Acidos carboxilicos de heteroarilo condensado como agonista del ppar |
| EP1651595A2 (de) * | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitinligaseinhibitoren |
| CA2576993C (en) | 2004-08-12 | 2013-09-24 | Amgen Inc. | Bisaryl-sulfonamides |
-
2005
- 2005-08-11 CA CA2576993A patent/CA2576993C/en not_active Expired - Fee Related
- 2005-08-11 US US11/203,006 patent/US7544702B2/en not_active Expired - Fee Related
- 2005-08-11 WO PCT/US2005/028673 patent/WO2006020830A2/en not_active Ceased
- 2005-08-11 AU AU2005272786A patent/AU2005272786B2/en not_active Ceased
- 2005-08-11 DE DE602005020313T patent/DE602005020313D1/de not_active Expired - Lifetime
- 2005-08-11 EP EP05790029A patent/EP1786782B1/de not_active Expired - Lifetime
- 2005-08-11 AT AT05790029T patent/ATE462697T1/de not_active IP Right Cessation
- 2005-08-11 ES ES05790029T patent/ES2343640T3/es not_active Expired - Lifetime
-
2008
- 2008-11-12 US US12/291,756 patent/US7893077B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005272786B2 (en) | 2011-12-22 |
| US20090221584A1 (en) | 2009-09-03 |
| DE602005020313D1 (de) | 2010-05-12 |
| EP1786782B1 (de) | 2010-03-31 |
| US7893077B2 (en) | 2011-02-22 |
| WO2006020830A2 (en) | 2006-02-23 |
| US20060084802A1 (en) | 2006-04-20 |
| AU2005272786A1 (en) | 2006-02-23 |
| US7544702B2 (en) | 2009-06-09 |
| EP1786782A2 (de) | 2007-05-23 |
| ES2343640T3 (es) | 2010-08-05 |
| CA2576993A1 (en) | 2006-02-23 |
| WO2006020830A3 (en) | 2007-04-12 |
| CA2576993C (en) | 2013-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE462697T1 (de) | Bisaryl-sulfonamide | |
| MX2009005053A (es) | Emulsiones bituminosas. | |
| TWI346660B (de) | ||
| WO2007031441A3 (de) | Verfahren zum vertropfen von flüssigkeiten | |
| ATE518010T1 (de) | Aktive oberflächengekoppelte polymerasen | |
| EP2047409A4 (de) | Zweistufige texterkennung | |
| DK1877390T3 (da) | Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf | |
| IN2012DN00035A (de) | ||
| TW200608961A (en) | Methods and reagents for the treatment of metabolic disorders | |
| EP1915670A4 (de) | Verfolgung und synchronisierung von teileinheitsänderungen | |
| WO2006122187A3 (en) | Treating and evaluating inflammatory disorders | |
| WO2009032754A3 (en) | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease | |
| EP1971752A4 (de) | Unterstützung des hebe- und senkmechanismus einer betonsäge | |
| MX2009002684A (es) | Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropico. | |
| WO2009046229A3 (en) | Animal waste removal device | |
| NO20070440L (no) | Behandling av nevropatisk smerte, fibromyalgi eller revmatoid artritt | |
| GB2464417A (en) | Security deterrent mark and methods of forming the same | |
| WO2007075852A3 (en) | Calcium channel antagonists | |
| DK2327792T3 (da) | Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme | |
| ATE357967T1 (de) | Emulsionen mit oberflächenmodifizierten organischen molekülen | |
| WO2006098998A3 (en) | Methods and compositions for modulating vascular integrity | |
| MX2007013262A (es) | Metodo de construccion y tratamiento de pozos. | |
| NO20062975L (no) | Anvendelse av T-kadherin som et mal | |
| DE502006005619D1 (de) | Dokument mit einem elektronischen gerät | |
| TW200740460A (en) | Pharmaceutical composition containing PPAR γ agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |